GLP-1s treat the root cause by rising insulin secretion, suppressing glucagon, and decreasing appetite
Around 27% said the treatment had no effect on their alcohol consumption, while 22% said they abstain from drinking
Compounded semaglutide is not approved nor evaluated for safety, effectiveness, or quality by FDA
The STEP trial program examining higher-dose semaglutide (2.4 mg weekly) for weight management demonstrated mean weight loss of 12% to 15% over 68 weeks in adults with obesity, significantly exceeding placebo
Pinzones work integrates advanced statistical modeling with practical applications, to translate physiological data into insights to enhance performance, recovery, and long-term well-being
Depot-specific regulation of NAD+/SIRTs metabolism identified in adipose tissue of mice in response to high-fat diet feeding or calorie restriction